NEW YORK (GenomeWeb) – Agilent Technologies said this week that its PD-L1 IHC 22C3 pharmDx assay has been labeled for an updated use in urothelial carcinoma in Europe. Doctors there can now use the assay to identify urothelial carcinoma patients who are ineligible for cisplatin but may respond to the Merck immunotherapy Keytruda as a first-line treatment option.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.